STEVEN SEGRAVES: Open Payments
NPI 1215916143 · LEAWOOD, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,790 in 240 payments from 21 companies in 2025. Trend: 2023 $1,405 · 2024 $3,741 · 2025 $3,790
Food & beverage: $3,790
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 43 | $680 |
| ABBVIE INC. | 37 | $533 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 32 | $434 |
| Vanda Pharmaceuticals Inc. | 12 | $324 |
| E.R. Squibb & Sons, L.L.C. | 23 | $265 |
| Neurocrine BioSciences, Inc. | 14 | $238 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $180 |
| Lundbeck LLC | 8 | $169 |
| Axsome Therapeutics, Inc. | 11 | $168 |
| Collegium Pharmaceutical, Inc. | 17 | $160 |
Products named: REXULTI, VRAYLAR, CAPLYTA, HETLIOZ, COBENFY, INGREZZA, ABILIFY ASIMTUFII, TRINTELLIX.
Industry payments across KS — which companies pay providers there.
